# Urolithin A Evidence by Cancer Type This section groups the Urolithin A oncology evidence into focused cancer-type pages as the evidence base becomes strong enough to support them properly. That structure keeps each cancer page easier to navigate and makes future updates simpler. ### Available pages * [**Colorectal Cancer**](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/colorectal-cancer.md) — strongest current evidence, including Wnt signalling, AKT1-related immune effects, and chemotherapy sensitisation * [**Pancreatic Cancer**](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/pancreatic-cancer.md) — one of the strongest mechanistic settings, with KRAS-pathway relevance, stromal remodelling, and anti-PD-1 sensitisation data * [**Prostate Cancer**](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/prostate-cancer.md) — most clinically advanced evidence, including androgen-receptor signalling, NK-cell data, and the active phase II trial * [**Breast Cancer**](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/breast-cancer.md) — subtype-based evidence across ER-positive, triple-negative, and HER2-positive contexts * [**Endometrial Cancer**](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/endometrial-cancer.md) — ERα and ERβ remodelling, G2/M arrest, and one of the cleaner hormone-biology settings for Urolithin A * [**Glioblastoma**](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/glioblastoma.md) — blood-brain-barrier penetration, Sirt1-FOXO1 signalling, and tumour-microenvironment findings * [**Liver Cancer (HCC)**](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/liver-cancer-hcc.md) — direct HCC cell-line findings plus wider hepatoprotective and gut-liver-axis relevance in chronic liver disease * [**Lung Cancer**](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/lung-cancer.md) — multiple independent NSCLC mechanisms, including EMT inhibition, autophagy-linked mTOR suppression, and in vivo xenograft evidence * [**Osteosarcoma**](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/osteosarcoma.md) — early anti-metastatic evidence focused on migration, invasion, and MMP2/MMP9 suppression * [**Bladder Cancer**](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/bladder-cancer.md) — unusually strong UMUC3 sensitivity, G2/M arrest, apoptosis, and plausible urinary-exposure relevance If a cancer type is not listed here yet, it can be added later as the evidence base grows. ### In this section * [Overview](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology.md) * [Evidence Summary](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/evidence-summary.md) * [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/anticancer-mechanisms.md) * [Immune Effects](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/immune-effects.md) * [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/synergistic-combinations.md) * [Urolithin A Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type.md) * [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/pharmacokinetics-and-metabolism.md) * [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/safety-and-interactions.md) * [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/dosing-and-timing.md) * [Sourcing Quality Urolithin A](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/sourcing-quality-urolithin-a.md) * [Sensitisation to Conventional Therapies](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/sensitisation-to-conventional-therapies.md) * [Antimicrobial, Antiviral & Terrain Support](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/antimicrobial-antiviral-and-terrain-support.md)

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

### Key References Urolithin A research overview and oncology applications\ Urolithin A in pancreatic cancer models and combination research\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.